Skip to main content

Table 2 Baseline characteristics of the study cohort

From: Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?

Variable All patients (n = 103)
Median age, years (IQR) 69 (65–76)
Sex, n (%)
 Female 16 (15.5)
 Male 87 (84.5)
Etiology, n (%)
 Alcohol 55 (53.4)
 Hepatitis B 13 (12.6)
 Hepatitis C 5 (4.9)
 NASH 9 (8.7)
 Hemochromatosis 3 (2.9)
 AIH/PBC/PSC 4 (3.9)
 Unknown/Other 14 (13.6)
Child-Pugh stage, n (%)
 A 44 (42.7)
 B 41 (39.8)
 C 7 (6.8)
 No cirrhosis 11 (10.7)
BCLC stage, n (%)
 0 0
 A 25 (24.3)
 B 65 (63.1)
 C 6 (5.8)
 D 7 (6.8)
 Median tumor size of the largest lesion, mm (IQR) 42 (30–60)
Tumor number, n (%)
 Unifocal 19 (18.5)
 Multifocal 80 (77.7)
 Diffuse growth pattern 4 (3.8)
Laboratory parameters, median (IQR)
 Albumin, g/L 31 (28–36)
 Bilirubin, mg/dl 1.44 (0.92–2.5)
 Platelet count, per mm3 111 (74–172)
 AST, U/l 61 (42–88)
 ALT, U/l 40 (25–59)
 INR 1.2 (1.1–1.3)
 AFP, U/l 25 (6–280)
Type of TACE, n (%)
 cTACE 29 (28.2)
 DEB-TACE 74 (71.8)
  1. Values are given as n (%) or median (interquartile range) unless otherwise noted. NASH, nonalcoholic steatohepatitis. AIH, autoimmune hepatitis. PBC, primary biliary cholangitis. PSC, primary sclerosing cholangitis BCLC, Barcelona Clinic Liver Cancer. AST, aspartate aminotransferase. ALT, alanine aminotransferase. AFP, alpha fetoprotein. cTACE, conventional transarterial chemoembolization. DEB-TACE, drug-eluting bead transarterial chemoembolization.